Overview

Anti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)

Status:
Enrolling by invitation
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this prospective controlled study is to obtain a multi-center safety and feasibility data on patients managed with anti-thrombotic monotherapy with HeartMate 3 LVAS.
Phase:
N/A
Details
Lead Sponsor:
Institute for Clinical and Experimental Medicine
Collaborator:
Abbott
Treatments:
Warfarin